On 12 February 2015, orphan designation (EU/3/15/1434) was granted by the European Commission to PsiOxus Therapeutics Ltd, United Kingdom, for chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions for the treatment of ovarian cancer.
This medicine is now known as enadenotucirev.
The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.
Please note that this product was withdrawn form the Union Register of orphan medicinal products in June 2021 on request of the Sponsor.
Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions (enadenotucirev)
Treatment of ovarian cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: